
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
Aesthetic Medical International Holdings Group Limited (PAIYY)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/26/2025: PAIYY (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -93.41% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.61M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 4024 | Beta -0.18 | 52 Weeks Range 0.12 - 0.90 | Updated Date 02/26/2025 |
52 Weeks Range 0.12 - 0.90 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.15 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -6.66% | Operating Margin (TTM) -4.86% |
Management Effectiveness
Return on Assets (TTM) -6.49% | Return on Equity (TTM) -242.08% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 36372627 | Price to Sales(TTM) 0.01 |
Enterprise Value 36372627 | Price to Sales(TTM) 0.01 | ||
Enterprise Value to Revenue 0.36 | Enterprise Value to EBITDA 14.11 | Shares Outstanding 47788000 | Shares Floating 16414002 |
Shares Outstanding 47788000 | Shares Floating 16414002 | ||
Percent Insiders - | Percent Institutions 0.04 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aesthetic Medical International Holdings Group Limited
Company Overview
History and Background
Aesthetic Medical International Holdings Group Limited (AIH) was founded in China and is a provider of aesthetic medical services. It went public through a reverse merger; its historical evolution involves strategic expansions within the Chinese market.
Core Business Areas
- Surgical Aesthetic Treatments: Offers a range of surgical procedures, including facial plastic surgery, breast augmentation, and liposuction.
- Non-Surgical Aesthetic Treatments: Provides non-invasive treatments such as laser skin resurfacing, botulinum toxin injections, and dermal fillers.
Leadership and Structure
Information on AIH leadership is limited and is based around the current board of directors. The organizational structure is based around treatment services for Aesthetic Medical treatments.
Top Products and Market Share
Key Offerings
- Facial Plastic Surgery: Includes procedures such as rhinoplasty, blepharoplasty, and facelifts. Competitors in this area include other clinics offering similar surgical procedures.
- Dermal Fillers and Botulinum Toxin Injections: Provides wrinkle reduction and facial contouring services. Competitors include Allergan (ABBV) and Galderma.
Market Dynamics
Industry Overview
The aesthetic medical industry is driven by increasing demand for appearance-enhancing procedures. Growth is fueled by disposable income and societal beauty standards.
Positioning
AIH is a prominent player in the Chinese aesthetic medical market; however, its US presence and influence is limited. Competitively, it relies on its local market expertise.
Total Addressable Market (TAM)
The global aesthetic medicine market is projected to reach several billion USD. AIH's position primarily focuses on the Chinese portion of this TAM.
Upturn SWOT Analysis
Strengths
- Established presence in China
- Wide range of aesthetic medical services
- Brand recognition in its local market
Weaknesses
- Limited international presence, US Market Exposure
- Dependence on the Chinese economy
- Regulatory risks in the aesthetic medical industry
Opportunities
- Expanding service offerings
- Acquiring smaller clinics
- Leveraging digital marketing
Threats
- Increased competition
- Changing consumer preferences
- Economic downturns
Competitors and Market Share
Key Competitors
- ABBV
- SNY
- ZTS
Competitive Landscape
AIH faces competition from larger international players and local Chinese clinics. Its success hinges on local market knowledge.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is based on expansion in China.
Future Projections: Future growth relies on capturing more market share in China, with uncertain prospects in the US.
Recent Initiatives: Recent initiatives focus on attracting younger patients.
Summary
Aesthetic Medical International Holdings Group Limited has a strong presence in China but limited exposure to the US market. Expansion and competition remain significant challenges. Success is tied to its ability to navigate the Chinese market effectively and remain competitive. A lack of public financial data hinders comprehensive analysis.
Similar Companies
- ABBV
- SNY
- ZTS
Sources and Disclaimers
Data Sources:
- Company press releases
- Industry reports
- Analyst estimates
Disclaimers:
Data provided is for informational purposes only and should not be considered financial advice. Market share figures are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aesthetic Medical International Holdings Group Limited
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-10-25 | CEO - | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 1286 | Website https://ir.aihgroup.net |
Full time employees 1286 | Website https://ir.aihgroup.net |
Aesthetic Medical International Holdings Group Limited provides aesthetic medical services in the People's Republic of China and Singapore. The company offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments, including minimally invasive and energy-based treatments, which include laser, ultrasound, and radiofrequency treatments. It also provides general healthcare and other aesthetic medical services, such as internal medicine, urology, gynecology, and obstetrics treatment services, as well as dentistry, dermatology, and hair loss treatment services. The company was founded in 1997 and is headquartered in Shenzhen, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.